A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

Authors:	Lillian M. Smyth Kelsey R. Monson Komal Jhaveri Alexander Drilon Bob T. Li Wassim Abida Gopa Iyer John F. Gerecitano Mrinal Gounder James J. Harding Martin H. Voss Vicky Makker Alan L. Ho Pedram Razavi Alexia Iasonos Philip Bialer Mario E. Lacouture Jerrold B. Teitcher Joseph P. Erinjeri Nora Katabi Matthew G. Fury David M. Hyman

Affiliation:	1.Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center (MSKCC),New York,USA;2.Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center (MSKCC),New York,USA;3.Department of Psychiatry, Memorial Sloan Kettering Cancer Center (MSKCC),New York,USA;4.Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC),New York,USA;5.Department of Radiology, Memorial Sloan Kettering Cancer Center (MSKCC),New York,USA;6.Department of Pathology, Memorial Sloan Kettering Cancer Center (MSKCC),New York,USA;7.Oncology Clinical Sciences, Regeneron Pharmaceuticals,Tarrytown,USA

Abstract:

Keywords:
本文献已被 SpringerLink 等数据库收录！